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Abstract
We conducted a discovery genome-wide association study with expression quantitative trait loci 
(eQTL) annotation of new-onset diabetes (NOD) among European Americans, who were exposed 
to a calcium channel blocker-based strategy (CCB strategy) or a β-blocker-based strategy (β-
blocker strategy) in the INternational VErapamil SR Trandolapril STudy. Replication of the top 
signal from the SNP*treatment interaction analysis was attempted in Hispanic and African 
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Americans, and a joint meta-analysis was performed (total 334 NOD cases and 806 matched 
controls). PLEKHH2 rs11124945 at 2p21 interacted with antihypertensive exposure for NOD 
(meta-analysis p=5.3×10−8). rs11124945 G allele carriers had lower odds for NOD when exposed 
to the β-blocker strategy compared with the CCB strategy [OR=0.38 (0.24-0.60), p=4.0×10−5], 
while A/A homozygotes exposed to the β-blocker strategy had increased odds for NOD compared 
with the CCB strategy [OR=2.02 (1.39-2.92), p=2.0×10−4]. eQTL annotation of the 2p21 locus 
provides functional support for regulating gene expression.
INTRODUCTION
Hypertension affects approximately 80 million Americans and 22% of adults worldwide,1, 2 
putting those affected at increased risk for cardiovascular morbidity, mortality, and diabetes 
mellitus (DM).1, 3 Blood pressure reduction with antihypertensive medications is crucial for 
reducing risk for adverse cardiovascular outcomes. Thiazide diuretics and β-blockers are 
commonly prescribed and effective antihypertensive drug classes, but consistent evidence 
suggests increased risk for new-onset diabetes (NOD) with these classes compared with 
placebo and other antihypertensives.4-10 The direct association between NOD and adverse 
cardiovascular outcomes remains controversial.10-16 However, individuals with concomitant 
prevalent DM and hypertension face an increased risk for adverse cardiovascular outcomes 
compared to those with hypertension alone.12, 13, 15
Among individuals treated with antihypertensive agents, there is substantial inter-individual 
variability with regard to NOD development. In addition to clinical risk factors, such as race, 
baseline glucose, dyslipidemia, and body mass index (BMI),5, 6, 17 genetic variation may 
contribute to the inter-individual variability for risk of developing NOD among those treated 
with antihypertensive agents. Genetic risk for type 2 DM has been well studied, and an 
enrichment of type 2 DM associations among expression quantitative trait loci (eQTL) 
variants has been observed.18, 19 Additionally, treatment with some classes of 
antihypertensives has been shown to influence the susceptibility of NOD and several 
susceptibility genes have been suggested to play a role. Candidate gene studies have 
associated previously identified type 2 DM or fasting glucose susceptibility genes, such as 
KCNJ1 and TCF7L2, and NOD in individuals exposed to the thiazide diuretic 
hydrochlorothiazide (HCTZ).20, 21 However, the genetic contribution to development of 
NOD, its interaction with antihypertensive drugs, and most importantly the underlying 
mechanisms remain poorly understood.
Therefore, we performed the first genome-wide association study (GWAS) to investigate 
single nucleotide polymorphisms (SNP) associated with differential risk for NOD in 
response to exposure to two commonly prescribed antihypertensive treatment strategies. 
Additionally, eQTL enrichment analyses were performed. The research was conducted in a 
case-control sample created from the INternational VErapamil SR Trandolapril STudy 
GENEtic Substudy (INVEST-GENES), which consists of elderly hypertensive individuals 
with documented coronary artery disease.22
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Study Design and Participants
INVEST was a multicenter, randomized clinical trial (clinicaltrials.gov: NCT00133692) that 
has been described previously.23 Briefly, hypertensive individuals ≥50 years old and with 
documented coronary artery disease were randomized to either a calcium channel blocker 
(Verapamil SR)-based treatment strategy (CCB strategy) or a β-blocker (atenolol)-based 
treatment strategy (β-blocker strategy), with HCTZ and trandolapril available as add-on 
agents in both strategies. Participants were followed for an average of 2.7 years for NOD, 
which was a pre-specified outcome. Among those who were DM-free at baseline, 
development of NOD was defined as any new occurrence of self/physician reported DM, or 
new use of a DM medication during the follow-up period.6 INVEST-GENES includes DNA 
samples from 5,979 INVEST participants from the United States, including Puerto Rico.22 
All study protocols were approved by local or central institutional review boards and all 
participants provided separate, voluntary, written informed consent for participation in 
INVEST and INVEST-GENES.
Within INVEST-GENES, a nested NOD case-control study was conducted. Cases were 
participants who developed NOD as defined above, and controls were those who remained 
DM free (were not diagnosed with DM and were not taking DM medications) during the 
entire follow-up period. Cases and controls were frequency-matched based on gender, race/
ethnicity, and age (by decade). Race/ethnicity information was self-identified and confirmed 
by principal component analysis (PCA) defined genetic ancestry (described below). From 
now onwards, race/ethnicity will be referred to as race throughout the rest of the document. 
Among those who were genetically confirmed to be of European ancestry, each case was 
frequency matched to three controls. For those who were genetically confirmed as Hispanic 
or African ancestry, each case was matched to two controls.
Genotyping, Quality Control (QC), and Imputation
DNA samples were genotyped at the RIKEN Center for Integrative Medical Sciences 
(Yokohama, Japan) using the Illumina OmniExpressExome Beadchip. Subsequently, 
individual and SNP level QC procedures were performed using PLINK (v1.07).24 Minor 
allele frequency (MAF) and genotyping call rates were assessed. Concordance of genetic sex 
to pedigree sex was evaluated via X-chromosome heterozygosity. Cryptic relativeness or 
sample duplication was assessed through genome-wide identity-by-descent analysis. 
Potential sample contamination was tested using the inbreeding coefficient. SNPs or 
individuals were removed if any of the following criteria were met: genotyping call rate 
<95%, mismatch of genetic sex with pedigree sex, sample duplication, or potential sample 
contamination. A PCA was performed using EIGENSTRAT on a linkage-disequilibrium 
(LD) pruned set of high-quality SNPs that passed QC, and genetic continental ancestry was 
determined based on PCA clustering.25 PCA was then performed within each defined 
genetic ancestry group to identify PCs that best summarized genetic structure and ancestry 
clusters for each race group. Hardy-Weinberg Equilibrium (HWE) was assessed for each 
SNP, and deviations were flagged.
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Genome-wide imputation was conducted at the RIKEN Center for Integrative Medical 
Sciences using the 1000 Genomes phase I, release 3, multiethnic haplotype dataset as a 
reference (released April 30, 2012) for all study participants. SNPs that passed QC with 
MAF >0.01 in any of the INVEST race groups or 1000 Genome reference populations 
(EUR/AFR/AMR) were included for imputation. Called SNPs were aligned to the forward 
strand on the human genome reference Build 37 and oriented to the 1000 Genomes 
reference and alternate alleles. SNPs with alleles that did not match those in 1000 Genomes 
were removed. The oriented genotypes were then phased using SHAPEIT2 (v.778)26 and 
genotypes were imputed using IMPUTE2 (v.2.3.0).27 After genome-wide imputation, SNPs 
with a quality information metric <0.4, which demonstrated lower imputation certainty, were 
excluded. Additionally, imputed SNPs with MAF<0.03 in each race group were excluded.
Statistical Analysis
Continuous characteristics are presented as mean and standard deviation, and categorical 
characteristics are presented as frequency and percentages. Unpaired two-sample Student t-
test and chi-square tests were conducted to compare the baseline characteristics between 
cases and controls by race groups.
Genome-wide SNP*Treatment interaction analyses with NOD development was conducted 
under an additive genetic model by race groups using logistic regression modeling. Analyses 
were performed using PLINK24 adjusted for age, gender, principal components for ancestry, 
INVEST treatment strategy, genotyping call rate between 95%-98%, and use of HCTZ 
and/or trandolapril add-on therapy. Because both HCTZ and trandolapril have been observed 
to affect risk for NOD development,8 exposure to these agents was included in the model. 
Genotype call rate between 95-98% was also included as a covariate in the model to prevent 
confounding from individual DNA quality. The discovery sample consisted of European 
Americans as they made up the majority of the population. Genome-wide significance was 
specified at an alpha level of 5×10−8. SNPs with an interaction p<1×10−6 in European 
Americans were considered to be of suggestive significance and were tested for evidence of 
association in Hispanics and African Americans. A replication was defined as SNPs having 
consistent direction of effect in Hispanics and African Americans with an interaction p-value 
that achieved the Bonferroni corrected significance level under a one-sided hypothesis.
A meta-analysis of all three race groups was performed on SNPs that replicated in Hispanics 
and African Americans using METAL.28 Heterogeneity across race groups was assessed 
using Cochran's Q test. Follow-up analyses for adjusted odds of NOD development by 
genotype were conducted using SAS 9.3 (Cary, NC) for top association SNPs under additive 
or dominant models as appropriate. We also performed analyses adjusting for BMI in 
addition to the prespecified covariates listed above for the top SNPs to determine whether 
the identified associations were driven by BMI.
Cis-eQTL Annotation and Enrichment Analysis
Since eQTL studies are generally better powered than GWAS to detect functional SNPs,29-31 
we annotated our findings in INVEST European Americans with eQTL results from the 
Genotype-Tissue Expression (GTEx) pilot analysis. The GTEx pilot results were acquired 
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from postmortem donors.31, 32 In accordance with the GTEx project, only eQTLs that act cis 
to the target gene (within ±1MB of the transcriptional start site) were evaluated due to power 
considerations.31, 32 Three adequately powered GTEx eQTL tissues with sample size >80 
were analyzed, including subcutaneous adipose and skeletal muscle, which are peripheral 
tissues sensitive to insulin, as well as whole blood, which is the most accessible tissue. SNPs 
with a nominal SNP-gene expression association (p<0.05) were defined as eSNPs in each 
selected tissue, and were included for evaluation of enrichment. This lenient eSNP definition 
allowed inclusion of more eSNPs and improved power to detect enrichment. Based on 
results from the genome-wide interaction analysis, cis-eQTL enrichment was assessed in 
each tissue separately. Additionally, the proportion of SNPs with an interaction p<0.05 were 
compared among the sets of eSNPs and non-eSNPs, and enrichment p-value was estimated 
using the Z statistic.
RESULTS
Baseline Demographics
Baseline characteristics of individuals included in this study (334 NOD cases and 806 
controls) are summarized in Table 1. In general, baseline characteristics were similar 
between cases and controls in each race group, with the exception of age (which was 
matched by decade) and BMI.
Genome-Wide Interaction Analysis and Between Race Confirmations
Genome-wide interaction analysis in European Americans did not identify SNPs that 
achieved genome-wide significance. However, two loci (containing 17 SNPs) demonstrated 
evidence of a suggestive association (interaction p<1×10−6) with risk for NOD 
(Supplementary Figure 1, Supplementary Table 1). Within each locus the SNPs are in 
high LD (r2>0.8) with each other, and thus represent two independent signals. The 
chromosome 2p21 locus contains THADA (thyroid adenoma associated) and PLEKHH2 
(Pleckstrin Homology Domain-Containing Family H Member 2) (Figure 1). The 4p14 locus 
consists of a cluster of toll-like receptor (TLR) genes (TLR1, TLR6, and TLR10) 
(Supplementary Figure 2), and contains the strongest signal (rs4833103, interaction 
p=1.6×10−7), which is located 8 kb 5’ of TLR1 and 10 kb 3’ of TLR6.
When evaluating these two independent signals in Hispanics and African Americans, 
rs11124945 at 2p21 was directionally consistent across race groups and achieved the 
Bonferroni corrected one-sided alpha of 0.05 in Hispanics (one-sided interaction 
p=1.56×10−2) and African Americans (one-sided interaction p=2.47×10−2). Meta-analysis of 
2p21 rs11124945 of all three race groups resulted in a p-value approaching genome-wide 
significance (meta-analysis p=5.33×10−8, Table 2). Overall, rs11124945 G allele carriers 
had lower odds for NOD when exposed to the β-blocker strategy compared with exposure to 
the CCB strategy [Odds Ratio (OR, 95% CI)=0.38 (0.24-0.60), p=4.02×10−5], while A/A 
homozygotes exposed to the β-blocker strategy had increased odds for NOD compared with 
exposure to CCB strategy [OR=2.02 (1.39-2.92), p=2.0×10−4] (Figure 2). Adjusting for 
BMI in the logistic regression model did not affect the level of significance (Supplementary 
Table 2). Supplementary Table 3 describes allele counts and HWE result of rs11124945. 
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The 4p14 signal observed in European Americans, although directionally consistent, did not 
achieve the corrected significance level in the Hispanics and African Americans.
Cis-eQTL Enrichment of NOD GWAS
Enrichment of cis-eQTL for pharmacogenomic associations was observed in subcutaneous 
adipose tissue, skeletal muscle tissue, and whole blood for NOD, as evidenced by the 
deviation from the null distribution in the Q-Q plots for all three tissues (Supplementary 
Figure 3). Additionally, a significantly higher proportion of SNPs with interaction p<0.05 
was observed among eSNPs compared to non-eSNPs in all three tissues (subcutaneous 
adipose: 5.0% vs 4.3%, Z=12.25, p<1.0×10−5; muscle skeletal: 5.0 % vs 4.3%, Z=12.69, 
p<1.0×10−5; and whole blood: 5.0 % vs 4.3%, Z=11.67, p<1.0×10−5, Supplementary Table 
4). These results represent a 1.16 fold enrichment among eSNPs compared to non-eSNPs in 
each tissue. Moreover, the two strongest loci in European Americans (2p21 and 4p14), 
displayed evidence of a tissue dependent eQTL-gene relationship among the tested tissues 
(Table 3).
DISCUSSION
Among European Americans in INVEST-GENES exposed to CCB based and β-blocker 
based antihypertensive strategies, we performed the first genome-wide investigation of SNPs 
associated with NOD development. SNP rs11124945, located in the second intron of 
PLEKHH2, was discovered in European Americans, was replicated in Hispanics and African 
Americans, and had the strongest evidence of an interaction with treatment strategy exposure 
for NOD development. Furthermore, genome-wide annotation with eQTLs information from 
the GTEx project provided functional support for the top GWAS signals and evidence for the 
notion that the identified signals are more likely to be true-positive associations. The GWAS 
was performed using well-characterized phenotypes and medication exposure information 
from the randomized INVEST clinical trial, which greatly reduces potential confounding. 
Moreover, our study contains an racially diverse population, providing a unique opportunity 
to assess genetic associations in Hispanics and African Americans, who are at higher risk for 
DM33 and NOD compared with individuals of European ancestry.6, 17, 34
PLEKHH2 may play roles in the linkage of kidney podocytes to the basement membrane, 
and actin stabilization,35 and SNPs within PLEKHH2 have been associated with diabetic 
nephropathy.36 Although the functional consequences of rs11124945 are incompletely 
understood, we observed differential risk for NOD by rs11124945 genotype and 
antihypertensive exposure across multiple race groups. When exposed to the β-blocker 
strategy versus the CCB strategy, G allele carriers had decreased risk for NOD, while A/A 
homozygotes had increased risk. This observation may suggest that for rs11124945 G allele 
carriers, treatment with a β-blocker based strategy would be preferred, while for A/A 
homozygotes, treatment with a CCB based strategy would be preferred. Within this 
INVEST-GENES GWAS, our observation that major allele carriers had increased risk for 
NOD when exposed to a β-blocker strategy is in line with data from other clinical trials, 
including the overall INVEST trial (n=22,576), which demonstrated that risk for NOD was 
higher in individuals treated with regimens containing a β-blocker.5, 6, 8
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PLEKHH2 rs11124945 is approximately 50 kb 5’ upstream of THADA, a gene with well-
established associations with type 2 DM,37 polycystic ovary syndrome (a phenotype 
characterized by insulin resistance and risk for type 2 DM),38, 39 and prostate cancer40 in 
previous GWAS. THADA may play a role in apoptosis and death receptor signaling, but its 
function requires further characterization.41 The THADA rs7578597 T allele has been 
associated with risk for type 2 DM and lower β-cell function, potentially via reduced β-cell 
mass.42 Although our observed association between rs11124945 and NOD risk is not driven 
by rs7578597 (r2=0.007, D'=1), rs11124945 is in LD with rs6544683 (r2=0.9, D'=1) that has 
tissue dependent eQTL associations, and could be in LD with other unknown functional 
variants. Given the association between THADA and type 2 DM, and its proximity to 
rs11124945, THADA represents a plausible candidate gene for NOD. Previous type 2 DM 
and polycystic ovary syndrome GWAS reported disease associations with THADA 
independent of BMI.37, 38 Similarly, we did not observe an effect of BMI on NOD 
association with rs11124945.
The 4p14 locus, consisting of TLR1, TLR6, and TLR10. TLRs are a family of 
transmembrane receptors that recognize pathogen- or damage-associated molecular patterns 
and are crucial in mediating the innate immune response.43 TLR2 and TLR4 play important 
roles in type 2 DM pathogenesis,44 and TLR1 and TLR6 form heterodimers with TLR2 
essential for TLR2 signaling.45 Activation of the TLR/NFκB pathway in conjunction with 
the NLRP3 inflammasome triggers IL-18 and IL-1β mediated inflammatory cascade, which 
results in monocyte recruitment and production of additional cytokines with deleterious 
effects on pancreatic β-cell insulin secretion and systemic insulin resistance.43-46 While the 
observed pharmacogenomic association at 4p14 needs further replication, the biology is 
compelling.
Our eQTL-based enrichment results demonstrate a deviation from the null hypothesis, which 
suggests higher probability that signals at 2p21 and 4p14 are true positive associations. 
Moreover, SNPs within 2p21 and 4p14 had functional support for regulating expression in a 
tissue-dependent manner, suggesting that they might regulate gene expression in other 
relevant tissues. It has been demonstrated that drug response associated SNPs are likely to be 
eQTLs and to regulate expression of multiple genes.30 We observed enrichment of NOD 
association among eSNPs compared to non-eSNPs. Previous studies demonstrated that 
eQTL SNPs are more likely to be associated with type 2 DM in relevant tissues,19, 47 and a 
trans-regulatory characteristic has been reported.48-50 Currently, GTEx is not sufficiently 
powered to provide a trans-eQTL reference panel. We examined cis-eQTL enrichment in 
available tissues relevant to DM pathophysiology with appropriate power. Exploration of 
eQTL enrichment using other key DM-related tissues, such as pancreatic islet, liver, and 
brain, can be examined when the information become available from GTEx.
We observed evidence of interaction with treatment strategies at the 2p21 locus, which has 
been previously associated with type 2 DM and related phenotypes, suggesting that there are 
potential overlapping pathways between NOD and type 2 DM. These conditions share 
clinical risk factors, such as race and BMI.5, 6, 17 Although the association between NOD 
and adverse cardiovascular outcome is in debate,10-16 DM of other etiologies independently 
contributes a two-fold excess risk of cardiovascular disease,53 and an increased 
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cardiovascular risk has been observed in individuals with NOD.12, 15 The majority of genetic 
markers for type 2 DM risk have been associated with primary defects in pancreatic β-cells,
18, 54, 55 which could lead to a reduced ability to produce insulin and maintain glucose 
homeostasis in the presence of environmental risk factors. Reduced pancreatic β-cell mass as 
a result of increased apoptosis has been hypothesized as a potential mechanism by which 
THADA affects type 2 DM risk.42 Taken together, our findings may suggest that when an 
individual has existing genetic risk for type 2 DM, introducing diabetogenetic 
antihypertensives like β-blockers and thiazide diuretics could serve as environmental risk 
factors, and promote deterioration of glucose homeostasis. Currently, the exact mechanism 
for the observed interaction between the 2p21 locus and treatment strategies remains 
unclear. Future studies, including functional characterization of these genetic signals, are 
needed to elucidate the mechanism. A better understanding of the genetic etiology of NOD 
in addition to other known risk factors could provide guidance for personalization of 
pharmacotherapy tailored to optimize benefit and minimize risk for adverse outcomes like 
NOD.
Study limitations include a relatively small number of NOD cases with no external 
replication since INVEST-GENES is one of the only genetic cohorts that consist of elderly 
adults with documented hypertension and coronary artery disease. Although sample size was 
limited, we conducted this study because pharmacogenomic SNPs generally have larger 
effect size than disease genetics SNPs.56 While our study had limited power, we included 
additional evidence provided from the cross race confirmation and the eQTL analysis to 
minimize the chance of reporting a spurious result. Even though the magnitude of effect of 
PLEKHH2 rs11124945 is smaller in Hispanics and African Americans, the direction of 
effect is consistent with what we observed in European Americans. In published 
pharmacogenomic studies, reported pharmacogenomic associations are often observed 
across race groups,57-59 although the magnitude of effect could be different due to 
population substructure. A cross race replication approach provides the advantage of 
increased power and the possibility to identify functional SNPs, as truly functional SNP 
associations should replicate across race groups.60, 61 Although we detected no genome-
wide significant associations in European Americans, our eQTL-based enrichment results 
demonstrate an improvement of the rate of false discovery when using eQTL information in 
disease-relevant tissues. Our results also show that our most highly ranked SNPs can be 
distinguished from “noise”, and that these SNPs have prior functional support for regulating 
expression in a tissue-dependent manner. Despite lacking an appropriate external replication, 
we observed associations in all race groups, and together with the eQTL results, we believe 
it is less likely to be a chance finding. Despite the limited power, this study represents the 
first investigation of SNP-treatment interactions for NOD, and provides valuable initial data 
to the field. Finally, there are differences in age and BMI comparing cases and controls in 
some race groups. However, age was included as a covariate in the analyses and additional 
analyses were conducted adjusting for BMI for the top association signal.
In conclusion, we conducted the first GWAS for NOD in a cohort with hypertension and 
coronary artery disease, and identified SNP rs11124945 at the 2p21 locus as having the 
strongest evidence of interaction with antihypertensive exposure and NOD development. 
rs11124945 G allele carriers had lower odds for NOD when exposed to the β-blocker 
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strategy compared with the CCB strategy, while A/A homozygotes exposed to the β-blocker 
strategy had increased odds for NOD compared with the CCB strategy. The 2p21 locus has 
functional support for regulating gene expression and contains both PLEKHH2 and THADA 
that are relevant to DM and related phenotypes. Genes and pathways influencing DM 
susceptibility could be important in determining an individual's genetic predisposition for 
NOD. These results along with enrichment of pharmacogenomic association among eQTLs, 
shed light on the underlying mechanism of NOD, and provide useful information for future 
studies. Further replication and functional characterization is warranted.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Regional plot at chromosome 2p21 locus for new-onset diabetes (NOD) association in 
INVEST European Americans
Regional SNP*Treatment interaction analysis results (−log p-value) are plotted for INVEST 
European Americans. Figure is generated using LocusZoom63. The diamond-shaped dot 
represent the SNP with lowest interaction p-value in the loci. The lower panel demonstrated 
the RefSeq genes.
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Figure 2. Forest plot of the PLEKHH2 rs11124945 pharmacogenomics association with New-
onset Diabetes (NOD)
This figure shows PLEKHH2 rs11124945 genotypes specific odds ratio and 95% confidence 
interval for NOD in each race groups and combined meta-analysis from the INVEST NOD 
case-control study (n = 1140). Point estimate was reported under a dominant genetic model 
for each genotype group, which represents higher risk for NOD in the CCB strategy or the 
β-blocker strategy. Interaction p-values for Hispanics and African Americans are one-sided.
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Table 1
Baseline characteristics of the INVEST-GENES NOD case-control study
Characteristics European Americans (n=552, 48%) Hispanics (n=471, 41%) African Americans (n=117, 10%)
Cases Controls Cases Controls Cases Controls
n=138 n=414 n=157 n=314 n=39 n=78
Age, years (mean ± SD) 65.9±8.7
69.1±9.4
** 64.4±10.2 64.1±9.7 63.5±10.8 64.6±10.3
Gender (male) 86 (62.3) 247 (59.7) 59 (37.6) 118 (37.6) 11 (28.2) 22 (28.2)




SBP, mmHg (mean ± SD) 146.9±17.7 149.1±17.5 149.5±19.9 146.8±18.1 152.3±18.6 151.0±21.7




    Smoking (ever) 72 (52.2) 208 (50.2) 46 (29.3) 98 (31.2) 15 (38.5) 25 (32.1)
    Left ventricular hypertrophy 19 (13.8) 51 (12.3) 30 (19.1)
36 (11.5)
* 6 (15.4) 15 (19.2)
    Transient ischemic attack 14 (10.1) 44 (10.6) 8 (5.1) 8 (2.6) 5 (12.8) 4 (5.1)
    Hypercholesterolemia 99 (71.7) 303 (73.2) 68 (43.3) 111 (35.4) 15 (38.5) 32 (41.0)
    Revascularization 73 (52.9) 200 (48.3) 6 (3.8) 14 (4.5) 7 (18.0) 9 (11.5)
Randomization arm (%):
    CCB strategy / 65 (47.1)/ 196 (47.3)/ 73 (46.5)/ 143 (45.5)/ 22 (56.4)/ 41 (52.6)/
    β-blocker strategy 73 (52.9) 218 (52.7) 84 (53.5) 171 (54.5) 17 (43.6) 37 (47.4)
Values are presented as number (percentage) unless otherwise noted.
BMI, body mass index; SBP, systolic blood pressure; DBP diastolic blood pressure; CCB, calcium channel blocker.
**
p < 0.001 between cases and controls
*
p < 0.05 between cases and controls
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Table 3
Tissue specific eQTL and gene association for top signals in INVEST European Americans















Skeletal muscle RP11-617D20.1 (KLF3 antisense RNA 1) 0.012
Whole blood KLHL5 0.014
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